awmsg logo



leuprorelin acetate (Prostap® SR DCS/Prostap® 3 DCS)


Reference No. 2419

Publication date:
13/01/2015


Appraisal information

leuprorelin acetate (Prostap® SR DCS/Prostap® 3 DCS) 11.25 mg powder and solvent for prolonged-release suspension for injection
leuprorelin acetate (Prostap® SR DCS/Prostap® 3 DCS) 3.75 mg powder and solvent for prolonged-release suspension for injection


Company: Takeda UK Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: 15/10/2014
AWMSG meeting date: 12/11/2014
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 3814
Ministerial ratification: 09/01/2015

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Leuprorelin acetate (Prostap® SR DCS/Prostap® 3 DCS) is recommended as an option for use within NHS Wales as neoadjuvant treatment prior to radiotherapy in patients with high risk localised or locally advanced prostate cancer.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download